Shamblott and Gearhart Application No.: 10/767,421 Filing Date: January 22, 2001

Page 2

## **AMENDMENTS TO THE CLAIMS**

Please amend claims 1, 22, 27-29, and 36-38 as set forth below. Claims 2-8, 14, 17-21, and 33 were previously canceled, without prejudice or disclaimer.

The current listing of claims replaces all prior listings.

1. (Currently Amended) A human embryoid body derived (EBD) cell characterized by: forming disaggregated single cells upon dissociation from embryoid bodies (EB) and adhesion to [[a]] defined extracellular matrix components substrate lacking a feeder layer; having the ability to be maintained in culture on the defined extracellular matrix components substrate in the absence of a feeder layer; and lacking detectable telomerase activity.

## 2-8. (Canceled)

- 9. (Previously Presented). The EBD cell of claim 1, wherein under suitable cell culture conditions the EBD cells proliferate for at least thirty population doublings without being immortal under said conditions.
- 10. (Previously Presented) The EBD cell of claim 9, wherein the EBD cells proliferate for at least sixty population doublings.
- 11. (Previously Presented) The EBD cell of claim 1, wherein the EBD cells proliferate under suitable cell culture conditions that are nonpermissive for proliferation of human embryonic germ cells.
- 12. (Previously Presented) The EBD cell of claim 1, wherein the EBD cells proliferate under suitable cell culture conditions lacking leukemia inhibitory factor, a fibroblast feeder layer, or both.

Shamblott and Gearhart

Application No.: 10/767,421 Filing Date: January 22, 2001

Page 3

13. (Previously Presented) The EBD cell of claim 1, wherein the EBD cells are transfectable with a retrovirus or a lentivirus or both.

- 14. (Canceled)
- 15. (Previously Presented) The EBD cell of claim 9, wherein the EBD cells are clonal.

Attorney Docket No. JHU1750-1

16. (Previously Presented). The culture of claim 15, wherein the EBD cells are clonally derived from a single EBD cell.

17-21. (Canceled)

- 22. (Currently Amended) A method of obtaining a human embryoid body derived (EBD) cell comprising:
  - (a) culturing primordial germ cells under conditions that are suitable for formation of a solid or cystic embryoid body having a 3-dimensional morphology;
  - (b) disaggregating the solid or cystic embryoid body under suitable enzymatic conditions to provide a constituent cell or embryoid body derived (EBD) cell; and
  - (c) culturing the EBD cell under conditions suitable to produce a population of proliferating EBD cells

wherein the cell is characterized as forming non-aggregated single cells upon dissociation from embryoid bodies (EB) and adhesion to [[a]] one or more defined extracellular matrix components substrate lacking a feeder layer; having the ability to be maintained in culture on the defined extracellular matrix components substrate in the absence of a feeder layer; and lacking detectable telomerase activity.

23. (Previously Presented) The method of claim 22 comprising selecting a single EBD cell from the EBD cells and culturing the single EBD cell to produce a clonal population of cells.

Shamblott and Gearhart

Application No.: 10/767,421 Filing Date: January 22, 2001

Page 4

Attorney Docket No. JHU1750-1

- 24. (Previously Presented) The method of claim 22 comprising culturing the EBD cell in a media comprising human basic fibroblast growth factor.
- 25. (Previously Presented) The method of claim 24 comprising culturing the-EBD cell in a media selected from the group consisting of RPMI 1640 supplemented with 15% FCS and media consisting essentially of hEGF, hydrocortisone, gentamicin, amphotericin-B, fetal bovine serum, VEGF, hFGF-2, heparin, recombinant human IGF-1 and ascorbic acid.
- 26. (Previously Presented) The method of claim 25 comprising culturing the EBD cell in a media consisting essentially of hEGF, hydrocortisone, gentamicin, amphotericin-B, fetal bovine serum, VEGF, hFGF-2, heparin, recombinant human IGF-1 and ascorbic acid.
- 27. (Currently Amended) The method of claim 22 comprising culturing the EBD cell on the defined extracellular matrix components a matrix.
- 28. (Currently Amended) The method of claim 27, wherein the one or more defined extracellular matrix components comprising culturing the EBD cell on a matrix that is are selected from the group consisting of collagen I, human extracellular matrix extract, and tissue culture-treated plastic.
- 29. (Currently Amended) The method of claim 28, wherein the one or more defined extracellular matrix components comprising culturing the EBD cell on a matrix are selected from the group consisting of collagen I and human extracellular matrix.
- 30. (Previously Presented) The method of claim 22 comprising culturing the EBD cell on a media that is not permissive for proliferation of the EG cells.

Shamblott and Gearhart

Application No.: 10/767,421 Filing Date: January 22, 2001

Page 5

Attorney Docket No. JHU1750-1

- 31. (Previously Presented) The method of claim 30 comprising culturing the EBD cell on a media lacking leukemia inhibitory factor, a fibroblast feeder layer, or both.
- 32. (Previously Presented) The method of claim 22 comprising culturing the population of proliferating EBD cells for at least 30 population doublings.
  - 33. (Canceled)
- 34. (Previously Presented) The EBD cell of claim 1, wherein the enzyme includes collagenase, dispase, or both.
- 35. (Previously Presented) The method of obtaining a human EBD cell of claim 22, wherein the enzyme includes collagenase, dispase, or both.
- 36. (Currently Amended) The method of claim 22, further comprising expanding the proliferating cells on one or more defined extracellular matrix components a matrix.
- 37. (Currently Amended) The method of claim 36, wherein the <u>one or more defined</u> extracellular matrix components matrix [[is]] are selected from the group consisting of collagen I, human extracellular matrix extract, and tissue culture-treated plastic.
- 38. (Currently Amended) A method of obtaining a human embryoid derived (EBD) cell comprising:
  - (a) culturing primordial germ cells under conditions that are suitable for formation of a solid or cystic embryoid body having a 3-dimensional morphology;
  - (b) disaggregating the solid or cystic embryoid body under suitable enzymatic conditions to provide a constituent cell or embryoid derived (EBD) cell; and
  - (c) expanding the EBD cell under conditions suitable to produce a population of proliferating EBD cells, wherein the EBD cells proliferate on one or more defined

Shamblott and Gearhart

Application No.: 10/767,421 Filing Date: January 22, 2001

Page 6

extracellular matrix components the matrix, and wherein the defined extracellular matrix components matrix [[is]] are selected from the group consisting of collagen I, human extracellular matrix extract, and tissue culture-treated plastic,

Attorney Docket No. JHU1750-1.

wherein the EBD cell forms non-aggregated single cells upon dissociation from embryoid bodies, whereby the EBD cell will adhere to [[a]] the defined extracellular matrix components substrate lacking a feeder layer, and whereby the EBD cell lacks detectable telomerase activity.